564 related articles for article (PubMed ID: 11329775)
1. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
4. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
5. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
[TBL] [Abstract][Full Text] [Related]
8. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
9. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
[TBL] [Abstract][Full Text] [Related]
10. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
12. Oral fluoropoyrimidines.
Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
15. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
17. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
[TBL] [Abstract][Full Text] [Related]
18. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
[TBL] [Abstract][Full Text] [Related]
19. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]